Monopar (MNPR) Stock Target Raised to $125 Following NDA Filing
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright has increased the price target for Monopar Therapeutics (MNPR) to $125 following the company's filing of a New Drug Application (NDA). This adjustment reflects confidence in Monopar's pipeline and upcoming events related to their drug developments. The new target may influence investor sentiment and trading volumes as the market reacts to the positive developments. For ordinary investors, understanding these changes helps gauge potential stock performance and investment opportunities in Monopar.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
